Physiomics PLC Two New Pre-Clinical Contracts (4987M)
31 July 2017 - 4:00PM
UK Regulatory
TIDMPYC
RNS Number : 4987M
Physiomics PLC
31 July 2017
Physiomics plc
("Physiomics") or ("the Company")
Two new pre-clinical contracts
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology
company, is pleased to announce that it has today signed two new
contracts with a global pharma company for Virtual Tumour
pre-clinical predictions relating to a new oncology target. This
marks the sixth year of collaboration with this company since a
first pre-clinical project was announced in March 2012.
The two contracts will be executed in parallel between now and
the end of the calendar year.
Jim Millen, CEO said: "We are delighted by these new contracts
which we believe are a sign of the client's long-term commitment to
Physiomics and its Virtual Tumour technology. We look forward to
continuing to work closely with them going forwards".
This announcement refers to a contract in the ordinary course of
business for Physiomics.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTLLFVRDEITFID
(END) Dow Jones Newswires
July 31, 2017 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024
